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Abstract
Background: Cigarette smoking is well-known to associate with accelerated skin aging as well as cardiovascular
disease and lung cancer, in large part due to oxidative stress. Because metabolites are downstream of genetic
variation, as well as transcriptional changes and post-translational modifications of proteins, they are the most
proximal reporters of disease states or reversal of disease states.
Methods: In this study, we explore the potential effects of commonly available oral supplements (containing
antioxidants, vitamins and omega-3 fatty acids) on the metabolomes of smokers (n = 11) compared to non-
smokers (n = 17). At baseline and after 12 weeks of supplementation, metabolomic analysis was performed on
serum by liquid and gas chromatography with mass spectroscopy (LC-MS and GC-MS). Furthermore, clinical
parameters of skin aging, including cutometry as assessed by three dermatologist raters blinded to subjects’ age
and smoking status, were measured.
Results: Long-chain fatty acids, including palmitate and oleate, decreased in smokers by 0.76-fold (P = 0.0045) and
0.72-fold (P = 0.0112), respectively. These changes were not observed in non-smokers. Furthermore, age and
smoking status showed increased glow (P = 0.004) and a decrease in fine wrinkling (P = 0.038). Cutometry showed
an increase in skin elasticity in smokers (P = 0.049) but not in non-smokers. Complexion analysis software (VISIA)
revealed decreases in the number of ultraviolet spots (P = 0.031), and cutometry showed increased elasticity (P =
0.05) in smokers but not non-smokers.
Conclusions: Additional future work may shed light on the specific mechanisms by which long-chain fatty acids
can lead to increased glow, improved elasticity measures and decreased fine wrinkling in smokers’ skin. Our study
provides a novel, medicine-focused application of available metabolomic technology to identify changes in sera of
human subjects with oxidative stress, and suggests that oral supplementation (in particular, commonly available
antioxidants, vitamins and omega-3 fatty acids) affects these individuals in a way that is unique (compared to non-
smokers) on a broad level.
Background
Cigarette smoking is well-known to associate with accel-
erated skin aging [1,2] as well as cardiovascular disease
and lung cancer, in large part due to cellular damage
from oxidative stress. Metabolites are downstream of
genetic variation, transcriptional changes and post-
translational modification of proteins. Hence, metabo-
lites can most accurately capture the status of disease
processes or reversal of disease processes [1]. Further,
the identification of specific biomarkers has recently
shed light on alterations that can occur in the metabo-
lome due to disease and environmental changes [2,3].
The adverse health effects of cigarette smoking are
well documented, and the basis of these effects is the
generation of free radicals. It has been estimated that
smoking a single cigarette can introduce about 1016
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reactive radicals into the body [4]. Cigarette smoke pro-
motes atherosclerosis and contributes to heart disease
[5,6]. In monozygotic twins where only one twin
smokes, the smoker is found to have significantly worse
skin damage, especially fine wrinkling [7].
Because the addictive qualities of cigarette smoking
can make this habit difficult to overcome, a potential
strategy to address the adverse biologic effects of smok-
ing might be to ingest substances that might absorb the
free radicals or mitigate their effects. One such category
of substances comprises the oral antioxidants, taken in
the form of supplements. However, the ability of oral
antioxidants to be absorbed through the gastrointestinal
tract, circulate through the bloodstream, and reach tar-
get organs, such as the skin or heart, is still an area of
active study [8].
Recently, metabolomic profiling has emerged as a
powerful tool to assess disease states, as well as the phy-
siologic effects of drugs or environmental exposures
[9,10]. For instance, metabolomic profiling has been
used to associate the metabolite sarcosine with prostate
cancer progression [3], defining metabolic individuality,
and revealing causal effects on genotype [11].
Our current short-term study explores whether a
combination of common over-the-counter antioxidants,
vitamins and omega-3 fatty acids might lead to detect-
able changes in the serum metabolites of smokers. We
explore whether these changes might be correlated with
physiologic or clinically visible changes in the most visi-
ble organ of the human body: the skin.
Materials and methods
Study design
This study was registered with Clinicaltrials.gov as pro-
tocol #10622 and performed in accord with the Declara-
tion of Helsinki principles.
Multiple commonly available over-the-counter antioxi-
dant compounds (many of which are vitamins) and
omega-3 fatty acids were used in the study because sup-
plements are taken in real life as ‘multivitamins’, oxida-
tive stress is known to deplete multiple antioxidants in
the skin, and multiple antioxidants are more effective
than a single antioxidant to combat oxidative stress [12].
Following approval by the Stanford Human Subjects’
Panel, healthy female volunteers provided informed con-
sent prior to all study procedures. Healthy female volun-
teers were recruited using newspaper, internet, and
radio advertisements, and paper postings in the San
Francisco Bay area. The arms of the study were (1) smo-
kers and (2) non-smokers. Inclusion criteria included
healthy subjects aged 50 to 70 years, Fitzpatrick skin
types I or II, a body mass index (BMI) in the normal
(18.5 to 24.9 kg/m2) or overweight (25.0 to 29.9 kg/m2)
categories, and sun or ultraviolet exposure not
exceeding 2 hours per day for one month prior to
enrollment. Healthy was defined as having no uncon-
trolled and/or active medical problems as determined by
a licensed physician. Exclusion criteria included: history
of cosmetic surgery to the face (facelifts, laser proce-
dures, and chemical peels), use of anti-aging medica-
tions (such as tretinoin) within the past 3 months prior
to enrollment, use of over-the-counter anti-aging creams
(excluding sunscreens) more than once per week in the
month prior to enrollment, and use of dietary supple-
ments, including vitamins, for one month prior to
enrollment. In addition, a control group of non-smoking
females under the age of 30 years and fulfilling all the
above criteria had their blood drawn for metabolomic
analysis to serve as a comparison group, but did not
take any supplements.
All subjects provided past medical histories, including
smoking history and current smoking status, menopau-
sal status, and hormone usage at baseline. Study patients
were also asked to refrain from UV exposure exceeding
more than 2 hours a day, including tanning bed use. In
addition, they were instructed to continue their usual
dietary intake and exercise, and, if they were smokers,
their usual cigarette smoking, without alteration during
the course of the study. Individuals who smoked at least
one cigarette a day were classified as current smokers,
and placed into the ‘smoker’ arm of the study. Subjects
received a commercially available nutritional supplement
containing multiple commonly available antioxidant
compounds (including catechins, carotenoids, lycopene,
and vitamins C, E and A), a number of common vita-
mins with no antioxidant properties, and omega-3 fatty
acids (Additional file 1). A complete list of ingredients
contained in the supplement (a commercially available
product manufactured according to Good Manufactur-
ing Practices), lifepak® nano, is listed in Additional file 1
in the Product Information Page. Currently, there are no
data on whether the nano size of the substances in the
supplement affects bioavailability, although co-enzyme
Q is five times more absorbable in nano size (NuSkin
International correspondence). Study subjects were
instructed to take the supplements twice daily, and were
given diaries to record compliance. The study flowchart
is provided in Figure 1.
Study subjects were seen for study visits at 4 weeks, 8
weeks and 12 weeks after enrollment. At each visit,
adverse events and concomitant medications were ascer-
tained. Serum was drawn at the baseline and week 12
visits only. Individuals who dropped out of the study or
were lost to follow-up prior to week 12 did not have
serum drawn and were not included in the study analy-
sis. Because of diurnal variation in serum metabolites,
all study procedures were conducted during a 5 hour
window from 8 am to 1 pm Pacific time.
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Serum metabolite analysis
Fasting serum samples were sent for metabolomic analy-
sis (Metabolon Inc., Durham, NC, USA) using both
liquid chromatography (LC) and gas chromatography
(GC) combined with mass spectroscopy (MS). The sam-
ple preparation process utilized the automated MicroLab
STAR® system from Hamilton Company(4970 Energy
Way, Reno, NV 89502 U.S.A). Recovery standards were
added prior to the first step in the extraction process
for QC purposes. Sample preparation was conducted
using a proprietary series of organic and aqueous extrac-
tions to remove the protein fraction while allowing max-
imum recovery of small molecules. The resulting extract
was divided into two fractions: one for analysis by LC
and one for analysis by GC. Samples were placed briefly
on a TuboVap® (Zymark 68A Elm Street, Hopkinton,
MA 01748) to remove the organic solvent. Each sample
was then frozen and dried under vacuum. Samples were
then prepared for the appropriate instrument, either
LC-MS or GC-MS.
The LC-MS portion of the platform was based on a
Surveyor HPLC system and a linear trap quadrupole
mass spectrometer (Thermo-Finnigan 81 Wyman Street,
Waltham, MA 02454 USA), which consisted of an elec-
trospray ionization source and linear ion-trap mass ana-
lyzer (Thermo Fisher Corporation 81 Wyman Street,
Waltham, MA 02454 USA). The mobile phase consisted
of 0.1% formic acid in H2O (solvent A) and 0.1% formic
acid in methanol (solvent B). The extract was loaded
onto an Aquasil column (100 × 2.1 mm, 3 μm,
ThermoElectron Corporation 81 Wyman Street, Wal-
tham, MA 02454 USA) via a CTC autosampler (Leap-
Technologies, Carrboro, NC, USA) and gradient eluted
(0% B, 4 minutes; 0 to 50% B, 2 minutes; 50 to 80% B, 5
minutes; 80 to 100% B, 1 minute; maintain 100% B, 2
minutes) directly into the mass spectrometer at a flow
rate of 200 μl/minute. The linear trap quadrupole moni-
tored positive and negative ions within a signal analysis
by consecutively alternating the ionization polarity of
adjacent scans.
The samples destined for GC-MS analysis were re-
dried under vacuum desiccation for a minimum of 24
hours prior to being derivatized under dried nitrogen
using bistrimethylsilyl-triflouroacetamide. The GC col-
umn was 20 m × 0.18 mm with a 0.18 μm film phase
consisting of 5% phenyldimethyl silicone and the tem-
perature ramp was from 40 to 300°C in a 16 minute
period. Samples were analyzed on a Thermo-Finnigan
Trace DSQ fast-scanning single-quadrupole mass spec-
trometer using electron impact ionization. The instru-
ment was tuned and calibrated for mass resolution and
mass accuracy on a daily basis.
Metabolite identification
Biochemicals were identified by comparison to library
entries of purified standards or recurrent unknown enti-
ties. The spectral files were searched using metabolomic
libraries created by Metabolon Inc. that contain about
2,400 commercially available compounds. The combina-
tion of chromatographic properties and mass spectra
Figure 1 Study flowchart.
Spitale et al. Genome Medicine 2012, 4:14
http://genomemedicine.com/content/4/2/14
Page 3 of 10
gave an indication of a match to the specific compound
or an isobaric entity. A total of 419 distinct metabolites
were identified and statistically analyzed for differences
between the two study arms (for a complete list of
metabolites, see Additional file 2).
Skin aging assessments
High quality digital facial photos (without makeup) with
standardized lighting and 45 degree head positioning
(Canfield VISIA ®Complexion Analysis System 253 Pas-
saic Avenue, Fairfield, NJ 07004-2524 USA) were taken
at baseline and week 12. These photos were subjected
to the Canfield computerized software attached to the
Complexion Analysis System to quantify physical prop-
erties of the cheek skin, including wrinkles, visible spots,
UV spots, and pores. These photos were assessed by
three dermatologist raters, blinded to the age and smok-
ing status of the study subjects for clinical parameters of
skin aging using a ten-point Likert scale modified from
validated skin aging scales. Characteristics scored
included visual softness, surface evenness, fine wrinkling,
deep wrinkling, pore size, elasticity, hydration, and glow.
At baseline and week 12, physiologic measurements of
facial skin barrier function and elasticity were assessed
using a transepidermal water loss meter (Delphin Vap-
ometer 62 Southfield Avenue, Suite 201, Stamford, CT
06902) and cutometer (Courage and Kazaska Cut-
ometer® MPA 580, Mathias-Brüggen-Str. 91 D-50829
Köln, Germany), respectively. The cutometer readings
used for this study were mode 1, R2 = Ua/Uf. The clo-
ser the value is to 1 (100%), the more elastic the curve.
To confirm intake of supplements, palmar skin carote-
noid levels were measured by Raman spectrophotometry
(Pharmanex Biophotonic Scanner, Provo, UT, USA).
Statistical analysis
Statistical analysis of the metabolomic and clinical data
using two-sided t-tests, z-tests, and ANOVA was carried
out using a combination of Microsoft Excel 2007, SPSS
16.0 (SPSS Inc., Chicago, IL, USA) Oracle 10.2.0.1
Enterprise Edition, GNU R, and Array Studio (OmicSoft
Corp 164 Quade Drive, Cary, NC 27513, USA). For all
analyses, missing values were imputed with the observed
minimum for that particular compound. The statistical
analyses were performed on natural log-transformed
data. Subject ratios of the 419 metabolites analyzed were
calculated by dividing the subject’s 12 week value by the
baseline value. Similarly, ratios were calculated for the
following continuous clinical parameters: VISIA®
assessed wrinkling, visible spots, UV spots, pore size,
elasticity, and transepidermal water loss. Other clinical
parameters included clinician’s assessments of fine
wrinkling, deep wrinkling, surface evenness, pore size,
elasticity, hydration and glow.
These metabolite ratios were then compared between
smokers and non-smokers by means of an analysis of
covariance (ANCOVA) model, with the clinical para-
meter ratio being the covariate. Due to sample size, a
separate ANCOVA model was fit for each clinical para-
meter. JMP version 8.0 was used to perform the analysis,
using log transformations of both the metabolite and
clinical parameter ratios. A P-value < 0.05 was taken to
indicate statistical significance while q-values were then
used to account for the false discovery rate of the identi-
fied P-values. For example, if a selected compound had
a P-value of 0.035 and a q-value of 0.1, roughly 10% of
all compounds with a P-value ≤0.035 would be a false
discovery.
To get an overall view of metabolite changes in the
study population at baseline and week 12, an average z-
score for all the metabolites was generated for each of
the two time points. The average z-score for the popula-
tion was termed mScore, with a score of 0.77 indicating
normal distribution. The average of the absolute values
of z-scores for all metabolites at baseline and week 12
were plotted to assess deviation from normal distribu-
tion. Z-score was calculated as:
z =
x− μ
σ
where x is a raw score to be standardized, μ is the
mean of the population, and s is the standard deviation
of the population.
To identify specific metabolites or metabolite groups
with the most significant change, heat maps demonstrat-
ing fold of change over 12 weeks of each metabolite in
smoker and non-smoker groups were generated, with P-
and q-values (to account for multiple comparisons) indi-
cating significance. Significant metabolites were searched
in existing metabolomic databases (for example, the
Human Metabolome Database [12], the Cofactor Data-
base: Organic and the Wiley Online Library [13]) to
cluster them into chemically or biologically related
categories.
Results
Study patients
Fifty-eight study subjects were enrolled: 15 current smo-
kers and 22 current non-smokers in the age category of
50 to 70 years, and 21 non-smokers in the age category
of < 30 years. Four smokers and five non-smokers dis-
continued the study prior to the 12 week time point
(Figure 1). These subjects were not included in the ana-
lysis since no subsequent serum samples were taken at a
second time point after enrollment.
The average age of smokers was 56.3 ± 5.0 years and
of non-smokers was 55.7 ± 6.3 years, P = 0.815 by
t-test. Current smokers smoked an average of 22.8
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pack-years. Body mass index, postmenopausal status,
hormonal therapy and caffeine intake were not signifi-
cantly different between the smoking group and non-
smoking group. The basic demographics of the study
subjects are shown in Table 1.
Study supplement usage was confirmed by increases in
subjects’ palmar skin carotenoid levels, as measured by
Raman spectroscopy. In smokers, counts indicating car-
otenoid levels increased an average of 15,055.25 ±
11,674.18 photon units at week 12; in non-smokers,
levels increased an average of 16,640.59 ± 13,595.16
units at week 12.
Metabolomic profiles
We identified and analyzed 419 metabolites, which con-
sisted of known metabolites as well as unknowns.
To evaluate the overall effect of the study supplement
on the study population, a z-score for each of the meta-
bolites was calculated at each baseline and week 12 (Fig-
ure 2). The average of the absolute values of z-scores
(termed mScore) for all metabolites at baseline and
week 12 were plotted to assess deviation from normal
distribution, with a normal distribution mScore equal to
0.77. At baseline, the mScore of the population was
0.930, with a significant number of smokers’ metabolites
(red dots) deviating from the non-smokers, or ‘healthy’
group (blue dots). At week 12 after supplementation,
the mScore was 0.865, with supplemented smokers’
metabolites becoming closer to the metabolomic profiles
of the non-smoking group.
The most significant changes in metabolites between
week 12 and baseline are depicted as heat maps (Figure
3), with green banding indicating decreases in metabo-
lite (fold change < 1), and red banding indicating
increases in metabolite (fold change > 1). Overall, the
non-smoking group (termed the ‘healthy group’) dis-
played increases in metabolites after 12 weeks, while the
supplemented smokers displayed decreases in metabolite
levels (Figure 2, left).
Compared to non-smokers, the smokers at baseline
had elevated levels of free fatty acids, which is consistent
with previously published research [13]. The most
prominent metabolomic changes after 12 weeks of study
supplement ingestion was a significant decrease in most
of the long chain fatty acids (LCFAs) in supplemented
smokers (listed on the right side of Figure 3). In the
supplemented smoking group, 11 out of the 16 LCFAs
(including palmitate, stearate, oleate, and linoleate) sig-
nificantly decreased. None of these 16 LCFAs changed
significantly in the non-smoking group. This suggests
that supplementation increasingly normalized the serum
lipid levels of LCFAs in smokers. Stearidonate was the
only LCFA that did not decrease over 12 weeks in the
smoker group. In both smokers and non-smoker groups,
stearidonate increased over 12 weeks. Of note, stearido-
nate is an omega-3-fatty acid, a component of the sup-
plement. This may explain increases in stearidonate in
both smoker and non-smoker groups.
Cofactors and vitamins that significantly increased
after 12 weeks of supplementation are listed in the bot-
tom right hand box of Figure 3 (shaded). Pantothenate,
alpha-tocopherol and pyridoxate were significantly
increased in non-smokers, as would be expected after
supplementation. Interestingly, the degree of increase in
smokers for alpha-tocopherol and pyridoxate was not
significant, suggesting possible increased conversion,
excretion or decreased absorption of these substances
compared to non-smokers. Another significant change
was an increase in bilirubin levels (part of the heme
degradation pathway) in non-smokers after supplemen-
tation, a change not seen in supplemented smokers. The
clinical and biologic significance of this change is cur-
rently unclear, although it is possible that the supple-
mented non-smokers increased heme breakdown or
decreased excretion of bilirubin compared to supple-
mented smokers.
Skin aging assessments
Smokers and non-smokers responded differently to
study supplementation for 12 weeks as measured by
quantitative skin aging parameters (Table 2). Smokers
showed a decrease in the number of UV spots (P =
0.03) but increased number of pores (P = 0.03) on
VISIA complexion analysis. On cutometry, there was a
Table 1 Basic demographics at baseline of study subjects who completed the study
Overall Non-smokers Smokers
Characteristic (N = 28) (N = 17) (N = 11) P
Mean age, in years (SD) 56.0 (5.6) 55.7 (6.3) 56.3 (5.0) 0.82
Mean BMI, in kg/m2 (SD) 24.7 (3.3) 24.0 (2.6) 25.5 (3.3) 0.24
Percentage postmenopausal at baseline 67.9 52.9 90.9 0.45
Percentage using hormone therapy at baseline and during study 14.3 23.5 0.0 0.19
Percentage of subjects with caffeine intake 96.4 94.1 100 0.09
The basic demographics at baseline of study subjects who completed the study were equivalent between smokers and non-smokers. P-values were calculated
using t-test or Fisher’s exact test (two-tailed). BMI, body mass index; SD, standard deviation.
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significant increase in elasticity (P = 0.05) in smokers. In
contrast, non-smokers’ values for these parameters did
not change (Figure 4).
In addition, clinical skin aging parameters that chan-
ged after 12 weeks of study supplementation (as
assessed by dermatologist raters blinded to smoking sta-
tus and chronological age) were not the same between
smokers and non-smokers. Supplemented smokers
showed decreased fine wrinkles (P = 0.04) and increased
glow (P = 0.00) but decreased hydration (P = 0.04). Sup-
plemented non-smokers showed decreased deep wrink-
ling (P = 0.00) and increased elasticity (0.01) (Table 3).
Adverse events
No serious adverse events occurred during the course of
our study. Adverse events that were deemed not related
to study supplement were headaches (14), body aches
(joint or muscle aches; 6) and common cold (5).
Adverse events deemed possibly related to study supple-
ment were loose stools (4), belching (4), and stomach
upset (1). When these adverse events were stratified by
smoker and non-smoker, none of the adverse events
were significantly different between the two groups. For
instance, of the 14 headaches, 3 episodes were in smo-
kers and 11 were in non-smokers, giving a P = 0.313
(Fisher’s exact test, two-tailed). For body aches, three
episodes were in smokers and three were in non-smo-
kers, P = 0.672.
Discussion
Limitations of this study include a relatively small sam-
ple size and its short-term nature (12 weeks only). In
addition, strict activity diaries kept by subjects might
better record confounders such as daily sun exposure
during the study.
Changes in the metabolomic profile and clinical
changes observed are associations and not necessarily
causative. It has been reported that increases in free
fatty acids induce oxidative stress by generating reactive
oxygen species and inflammation by increasing levels of
NF-kB [14-16]. Since high levels of fatty acids both pro-
mote and indicate a high level of oxidative stress and
inflammation, the antioxidants in the supplement could
alleviate these stressors. Future studies into histologic or
molecular changes might better characterize the precise
changes occurring in the skin. While we are able to
detect particular orally ingested antioxidants such as
carotenoids in the skin, quantitative measures of other
antioxidants (such as catechins) in the skin can be diffi-
cult. Measurable increased levels of these antioxidants in
the skin would bolster the contention that orally
ingested supplements reach the skin and can effect
change.
Non-smokers in our study experienced fewer overall
changes in metabolite levels, but an increase in metabo-
lites within the vitamin/cofactor pathways. One explana-
tion for this observation is that, upon antioxidant and
Figure 2 Decreased deviation of metabolites from normal distribution after 12 weeks of study supplement, most notably in the
smoker group. Scatterplots showing absolute values of z-scores for all metabolites at baseline and after 12 weeks of taking the study
supplement. The mScore is an average of all z-scores in the entire population. An mScore of 0.77 indicates a normal distribution. Red spot =
smokers; blue spot = non-smokers.
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Figure 3 Heat maps demonstrating fold change of metabolites in smokers and non-smokers. The heat maps show that smokers had
significantly decreased levels of (long chain fatty acids) but not the cofactors and vitamins listed below, after 12 weeks of study
supplementation. Green band = decrease; red = increase
Table 2 Differences in facial skin aging parameters (by VISIA Complexion Analysis software), elasticity and
transepidermal water loss after 12 weeks of study supplementation
Skin aging
parameter
Overall (N = 28) Non-smokers (N = 17) Smokers (N = 11)
Mean SD P Mean SD P Mean SD P
Wrinkling +0.036 14.046 0.99 -4.882 11.050 0.09 +6.615 14.239 0.12
Visible spots +2.393 7.440 0.10 +1.235 7.471 0.51 +3.154 7.414 0.15
UV spots -4.536 30.426 0.44 +5.000 28.588 0.48 -17.692 26.196 0.03
Pores +2.857 9.099 0.11 -0.235 7.496 0.90 +6.385 9.341 0.03
Elasticity +0.081 0.276 0.13 +0.020 0.274 0.77 +0.160 0.270 0.05
Transepidermal water loss (g/m2 h) -0.807 6.674 0.53 -0.941 5.459 0.487 -0.600 8.515 0.82
Smokers showed a significant decrease in UV spots and improvement in elasticity by cutometry measurement. However, smokers also displayed increased pore
count. Values reported are in percentiles, except for UV spots, which are reported as absolute values. Higher percentiles represent an improvement in a
parameter. Positive numbers indicate increase, negative numbers indicate decrease. SD, standard deviation.
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vitamin supplementation, non-smokers may have had a
surplus in vitamins and cofactors that remained uncon-
sumed. Previous studies have shown that cigarette
smoke directly depletes the levels of circulating antioxi-
dants and vitamins, such as ascorbate, alpha-tocopherol,
beta-carotene, lycopene, and retinol [17,18]. When tak-
ing these supplements, therefore, antioxidants and vita-
mins might be consumed in smokers, but left as excess
in non-smokers. This supports a model in which smo-
kers would benefit more from supplements than non-
smokers.
We acknowledge that the number of cigarettes
smoked per day may affect the metabolites present [19].
The total pack-years smoked varied widely in our study
population: the amount ranged from 4.2 to 37.5 pack-
years. Although there were variations in the amount of
pack-years, we instructed the participants to not change
their habits, especially the amount they smoked. From
the metabolomic analysis, the levels of cotinine, a well-
known metabolite of nicotine [20], did not significantly
change in either group after 12 weeks of supplementa-
tion. This demonstrates that the smokers did not have
drastic changes in smoking habit, suggesting that the
observations we observed may have been related to the
concentration of free radical oxygen species entering the
circulatory system from supplementation. Further stu-
dies in which the amount of smoking are controlled
could explore whether a minimum amount of smoking
is required to detect significant metabolomic changes as
well as define maximum levels of smoking beyond
which supplementation might have limited benefit.
The decrease in the mScore of the study population
toward a normal distribution (especially in the supple-
mented smokers) and the alteration of metabolomic
heat maps in supplemented smokers suggests that the
study supplement may be able to reduce the amount of
metabolites generated in pathways affected by smoking.
Smokers displayed more changes in their metabolome
than non-smokers after study supplementation, most
notably significant decreases in their LCFAs.
Of note, cigarette smoking not only introduces free
radicals that promote atherosclerosis and increase the
risk of cardiovascular disease [5,6], it has also been
linked to changes in lipid metabolism and increased
levels of free fatty acids in blood [13,21,22]. An addi-
tional explanation for the change in fatty acid composi-
tion with study supplementation is that peripheral
lipolysis is attenuated and possibly accompanied by
improved mitochondrial function. Lipolysis is a hallmark
of insulin resistance, and has been shown to be elevated
in smokers [23,24]. Any compounds within the study
supplement that affect insulin sensitivity could result in
decreased lipolysis and decreases in levels of LCFAs, as
detected in this study. Also, components in the supple-
ment that might improve mitochondrial function could
Figure 4 Patient skin glow and UV spots. (a, b) Example of an
increase in glow at week 12 (b) compared to week 0 (a) as
determined by a panel of four blinded dermatologists. (c, d)
Example of a decrease in UV spots at week 12 (Figure d) compared
to week 0 (c) in a participant as determined by VISIA Complexion
Analysis System.
Table 3 Differences in clinical skin aging parameters after 12 weeks of study supplementation as assessed by
dermatologist raters
Clinical skin aging
Parameter
Overall (N = 28) Non-smokers (N = 17) Smokers (N = 11)
Mean SD P Mean SD P Mean SD P
Fine wrinkling -0.571 2.516 0.24 +0.235 1.821 0.60 -1.769 2.743 0.04
Deep wrinkling +0.033 3.054 0.95 -1.853 1.579 0.00 +2.500 2.754 0.01
Surface evenness +0.429 1.874 0.24 +0.882 1.996 0.09 +0.154 1.819 0.77
Elasticity +0.161 2.415 0.73 +1.353 1.730 0.01 -1.115 2.468 0.13
Glow +1.179 3.151 0.06 +0.235 3.073 0.76 +2.538 2.570 0.00
Hydration -0.786 2.234 0.07 +0.294 0.985 0.24 -1.846 2.824 0.04
Smokers showed decreased fine wrinkles and increased glow, but decreased hydration. Non-smokers showed decreased deep wrinkling and increased elasticity.
Values are the average of scores given by the four raters. Negative values indicate decrease, positive values indicate increase. P-values calculated using two-sided
t-tests. SD, standard deviation.
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allow for fatty acids and amino acids to be consumed
more efficiently. It is possibly a combination of
improved insulin sensitivity and mitochondrial function
that causes the decline in fatty acids and amino acids.
Evidence that supports this idea is that two markers of
excessive carbon flow into the tricarboxylic acid cycle,
beta-hydroxybutyrate and 2-hydroxybutyrate, decline
with supplementation. These arise when either too
much carbon is produced relative to tricarboxylic acid
cycle capacity or the tricarboxylic acid cycle is not oper-
ating at full capacity. It also can be seen that these mar-
kers changed (only significantly for beta-
hydroxybutyrate) for the non-smokers as well. Overall,
these observations would suggest that the supplement
improves energy metabolism for both groups but that
the non-supplemented smokers simply have a more pro-
nounced issue of higher levels of peripheral lipolysis and
the fatty acids that accompany this. These observations
suggest a direct link between smoking and the fatty acid
composition of our sample set.
Further studies will be required to identify the specific
components of oral supplementation contributing to the
metabolomic changes seen in this study. In addition,
further studies will need to delineate whether the
decreases in LCFAs are beneficial or detrimental to
overall health status. In our current study, for instance,
smokers’ skin improved with respect to elasticity mea-
surements and clinical appearance of fine wrinkles, glow
and hydration but displayed worsened deep wrinkling
appearance after 12 weeks of study supplementation. It
has been observed previously that increased fatty acid
content in the skin regulates the healing process
through cell-surface interactions [25]. In addition,
longer-chained fatty acids have garnered a significant
amount of attention for their role in skin health, which
has revealed that animal models with deficient essential
fatty acids experienced increased water loss through the
skin [26]. These results suggest that fatty acids are a cri-
tical component of skin cell morphology and health and
further supports a link between our metabolic observa-
tions and our clinical observations.
While smoking can be regarded as a ‘disease condi-
tion’ worthy of possible ‘treatment’ with oral supplemen-
tation, it is unclear whether healthy individuals such as
non-smokers would benefit from oral supplementation.
In fact, there are large epidemiologic studies suggesting
that over-supplementation of particular nutrients can be
detrimental to health [27-29]; hence, further exploration
into the metabolic alterations that occur due to supple-
mentation and their role in organ phenotypes is needed.
Conclusions
Overall, our current pilot study suggests that metabolo-
mic changes in cigarette smokers can be altered through
oral supplementation and that these effects are different
between smokers and non-smokers. Clearly, the overall
and specific health consequences of these metabolomic
changes need further exploration and are beyond the
scope of this current study. Nevertheless, our study sug-
gests that metabolomics can be a meaningful tool to
assess the complex effects of oxidative stress in human
subjects, and that it is possible to correlate clinically sig-
nificant end-organ changes such as skin aging para-
meters with metabolomic changes. Characterization of
the nature of these connections merits further study.
Additional material
Additional file 1: Table S1 - heat map of statistically significant
biochemicals profiled in this study. Shaded cells indicate P ≤ 0.05 (red
indicates that the mean values are significantly higher for that
comparison; green values significantly lower). Note the statistical
comparison legend: *Group A = smokers; †group C = healthy.
Additional file 2: Table S2 - adverse events during study and fold
change of metabolomic profiles of smoking group after 12 weeks
of antioxidant supplementation.
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